Clinuvel drug kicks off EU project to boost patient role in benefit-risk review
This article was originally published in Scrip
Executive Summary
In a move intended to give patients more of a say in the evaluation of new drugs, the European Medicines Agency has begun a project under which patients will be invited to take part in certain benefit-risk discussions at meetings of its main scientific committee, the CHMP. The project has kicked off with Clinuvel's Scenesse (afamelanotide), a new drug intended to treat the rare disease erythropoietic protoporphyria (EPP).